Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment.
• Immune-related adverse events (irAEs) are common with ICIs.
• Thyroid dysfunction (TD-irAEs) is a frequent irAE, but its prognostic significance is unclear.

Purpose of the Study:

• To investigate the characteristics of TD-irAEs in cancer patients receiving ICIs.
• To assess the association between TD-irAEs and clinical outcomes, including response and survival.

Main Methods:

• Single-center retrospective analysis of 238 cancer patients treated with ICIs.
• Evaluation of TD-irAE incidence, timing, and association with objective response rate (ORR) and overall survival (OS).
• Multivariable-adjusted regression and Cox proportional hazards models were used.

Main Results:

• Nearly 30% of patients developed TD-irAEs, with higher incidence in combination therapy.
• Patients with TD-irAEs demonstrated significantly higher ORR (60% vs 42.3%) and longer OS (45 vs 16 months).
• TD-irAEs were independently associated with a reduced risk of progression (77%) and mortality (47%).

Conclusions:

• TD-irAEs are a common occurrence in patients treated with ICIs.
• The development of TD-irAEs appears to be a favorable prognostic marker, associated with improved treatment response and survival.
• Further research is warranted to understand the underlying mechanisms and clinical implications.